Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

PURPOSE: ERBB2 exon 20 insertions (20ins) have been identified as oncogenic drivers in lung cancers. Lung cancer patients with 20ins benefit from afatinib. However, response heterogeneity was observed in patients harboring different 20ins subtypes. In this study, we interrogated clinical characteris...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Onco Targets Ther
Prif Awduron: Liu, Zhefeng, Wu, Lin, Cao, Jun, Yang, Zhe, Zhou, Chengzhi, Cao, Liming, Wu, Hao, Shen, Haibo, Jin, Meiling, Zhang, Yong, Mao, Xinru, Xiang, Jianxing, Ma, Ke, Li, Bing, Zhang, Tengfei, Hu, Yi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2018
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
https://ncbi.nlm.nih.gov/pubmed/30425522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173391
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg